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ABSTRACT 
Background: Lung cancer is one of the most common malignancies in the world. About 80–85% of lung cancers are non-
small cell lung cancer (NSCLC). The development of therapeutic agents targeting products of epidermal growth factor 
receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) rearrangements has significantly improved survival 
in patients with NSCLC. Thus, the patients eligible for the treatment should be selected through appropriate molecular tests. 
Objective: The main objective was to study the distribution of NSCLC and its genetic mutations, in the patients of Eastern 
India. Methodology: A prospective study was carried out among 228 patients, in a tertiary care hospital of Eastern India 
during a period of 2 years from January 2016 to January 2018. We have included all the patients who were screened and 
found to have lug carcinoma. The detailed clinical history of the patients was recorded. We have used techniques such as 
radiology, histopathology, immunohistochemistry (IHC) and molecular study by FISH technique. Results: Out of 138 cases 
of NSCLC on histopathology 78 cases (56.7%) were reported as squamous cell carcinoma, 46 cases (33.3%) as 
adenocarcinoma and 14 cases (10.1%) as NSCLC. IHC was used for categorization of NSCLC cases which showed 
adenocarcinoma in 4 patients and squamous cell carcinoma in 10 patients. EGFR exon 19 deletion mutation was the 
predominant mutation in adenocarcinoma. Conclusion: Molecular study for genetic analysis has improved the scope for 
targeted therapy in Nonsmall cell carcinoma patients, thereby reducing mortality and morbidity in cases of lung carcinoma. 
Key words: Non-small cell lung cancer, Adenocarcinoma, EGFR mutation, ALK mutation, smoking. 
 
ung cancer is the most common cause of cancer 
deaths with approximately 1.4 million deaths 
worldwide annually [1]. Owing to the absence of 
clinical symptoms and effective screening programs, most 
of the patients have advanced stages or metastatic disease 
at the time of presentation [1]. Deaths in the USA 
attributable to lung cancer, are more than the next three 
most common cancers combined [2]. WHO classifies non-
small-cell lung cancer (NSCLC) as adeno carcinoma, 
squamous cell carcinoma and the subtypes of large-cell 
carcinoma–adeno squamous, sarcomatoid carcinoma [2,3].  
In the past, an increased rate of lung carcinoma among 
the male population was seen, predominantly in the 
smokers [3]. It is well known that smoke exposure can lead 
to well-characterized series of morphological changes of 
the bronchial epithelium progressing from basal cell 
hyperplasia to metaplasia, severe dysplasia to carcinoma in 
situ and, finally, frank carcinoma [3]. This series of 
changes is primarily associated with the squamous sub-
type of NSCLC. At present, NSCLC accounts for more 
than 85% of lung cancers in western countries, with 20–
30% of NSCLC occurring in non smokers [4]. This finding 
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has coincided with the discovery that a proportion of lung 
cancers occurring in non or light smokers, are driven by 
oncogenic mutations which, when selectively inhibited, 
can lead to dramatic tumor regression and prolonged 
survival [5].  
Hence, targeted therapies for genes such as epidermal 
growth factor receptor (EGFR), anaplastic lymphoma 
kinase (ALK) and KRAS have become the hotspot of 
attention and study in lung cancer treatment for the last 10 
years. In the past, these two molecular alterations have 
been viewed as mutually exclusive, but recent cases of 
lung cancer with concurrent EGFR mutation and ALK 
rearrangement have been identified [5,6]. Clinical 
guidelines have now incorporated molecular testing and 
the use of drugs targeting those genes [6]. The aim was to 
study the distribution of the various histological subtypes 
of NSCLC, spectrum of mutations, and its use for targeted 
therapy and better prognosis. 
METHODS 
This prospective study was conducted from January 2016 
to January 2018 in a tertiary care hospital, Kolkata, West 
Bengal, India. After getting the ethical committee approval 
and informed consent from the patienst we have included 
all the cases diagnosed as lung carcinoma, on 
histopathology. Cases, who were diagnosed as 
nonmalignant on histopathology, were excluded from the 
study. All the 228 patients reported to the chest OPD with 
various pulmonary complaints in a tertiary care hospital of 
eastern India, within our study period. Their detailed 
clinical history (including smoking history) and 
radiological findings were noted.  
Chest X-ray and contrast enhanced cytotopography 
(CECT) of lung followed by CT guided Trucut biopsy of 
lung lesions were performed. Patients were selected for CT 
guided Trucut biopsy on the basis of their radiological 
findings such as solid homogenous or cavitary mass/ 
consolidation in one or both of the lung fields.Prior to the 
biopsy, complete hematological profile of the patient 
including coagulation profile (PT/INR) was obtained. 
Immunohistochemistry (IHC) was done for those cases 
where categorization of the carcinoma was not possible on 
histopathological examination alone. Molecular study by 
Fluorescent in situ Hybridization (FISH) technique using 
the paraffin blocks was carried out in all the cases of lung 
carcinoma (detected on histopathology), to detect ALK 
and EGFR mutations. Other superadded features like 
pleural effusion, pleural thickening, the shift of the trachea 
and mediastinal lymphadenopathy, were the important 
findings on radiology. 
A correlation study was done based on the observations 
from radiological, histopathological and molecular study 
findings of patients reported as Lung carcinoma on biopsy. 
The data were calculated manually and the results were 
noted. 
RESULTS 
Among 228 cases of lung lesions studied, 156 cases were 
reported as lung carcinoma of which, 138 cases (88.5%) 
had NSCLC and small cell carcinoma was diagnosed in 18 
cases (13.05%) (Table1). Predominant clinical presentation 
among the patients was cough, chest pain, and 
breathlessness. Among 228 patients, male patients were 
predominant (82.5%) with the age ranging from 46 to 74 
years in males while 52 to 67 years in females. Patients 
were from urban and rural areas of different parts of West 
Bengal.  
Table 1: Distribution of Lung Lesions 
 On histopathological examination alone, 78 cases 
(56.7%) were reported as squamous cell carcinoma, 46 
cases (33.3%) as adenocarcinoma and 14 cases (10.1%) as 
NSCLC-NOS. IHC was used for categorization of 
NSCLC-NOS cases which resulted in 4 as adenocarcinoma 
and 10 as squamous cell carcinoma (Table 2). Male 
predominance was seen in all cases of NSCLC (3:1 in 
squamous cell carcinoma and 2.6:1 in adenocarcinoma 
cases). The age ranged from 63-65 yrs in males and 47-55 
yrs in females. Middle-aged females with no smoking 
habit showed an increased incidence of adenocarcinoma. 
Out of 156 patients, 140 had a history of smoking for a 
minimum of 11 years. A molecular study using FISH 
technique was carried out in 134 cases. Out of 50 cases 
diagnosed as adenocarcinoma, 12 cases (24.0%) showed 
EGFR deletion mutation of exon 19 and 4 cases (8.0%) 
Histology (n=228) Cases 
Small cell carcinoma 18 
Squamous cell carcinoma 78 
Adenocarcinoma 46 
Non small cell Ca(non differentiated) 14 
Others(SFT, TB, NHL, METS,  Pneumocyte 
hyperplasia, germ cell tumor) 
60 
In conclusive  12 
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showed EGFR deletion mutation of exon 21. ALK was 
negative in all cases. Four cases of morphologically 
diagnosed squamous cell carcinoma showed EGFR 
deletion mutation of exon 19. On follow up, the patients 
were started on targeted therapy and no mortality was 
reported till date. 













NSCLC-NOS 14 Adenocarcinoma- 
04 Squamous cell 
carcinoma- 10 
DISCUSSION 
The molecular basis of lung cancer is complex and 
heterogeneous. The molecular changes (genetic, 
epigenetic, protein expression) and the improvements in 
understanding of the functional expressiveness of these 
changes have potential effects on the diagnosis, prognosis, 
and treatment of lung cancer [7]. EGFR mutations in 
NSCLC are seen in the intra cellular tyrosine kinase 
domain. Deletion of exon 19 is most commonly followed 
by missense mutations, exon 21, a single nucleotide point 
mutation leading to a single amino acid change from 
leucine to arginine at codon 858 [5,7].  
 Ture et al in their study of 132 patients of NSCLC 
found 30.3% (19) cases of lung carcinoma had EGFR exon 
19 mutation. Eighteen of these cases were histologically 
diagnosed as adenocarinoma [6]. Marino et al found EGFR 
mutation in 32.7% cases (336/977) of lung carcinoma in a 
Chinese population [3]. In the present study, we found 
EGFR mutation in 32% cases (16/50) out of which exon 
19 mutation was 24% (12/50) and exon 21 mutation was 
8.0% (4/50). Sweis et al, in their retrospective study of 20 
cases of NSCLC, found the disease control rates in patients 
treated with EGFR inhibitors was 46% (6/13) [4]. Wang et 
al in their study of 300 cases of NSCLC found ALK 
rearrangement mutation in 4.33% cases of adenocarcinoma 
(13/300) [8]. In our study, ALK mutation was found to be 
negative in all cases. Won et al in their study screened 
1458 patients, out of which 91 patients were selected for 
molecular study by direct sequencing FISH method. EGFR 
and ALK mutations were found to be 42.4% and 6.3% 
respectively. Concomitant mutations were found in 4.4% 
(4 cases) [9]. Lee T et al in their study found that 12 out of 
6637 patients had concomitant mutations [10]. In our 
study, none of the cases showed a concomitant mutation. 
Concomitant genetic alteration of NSCLC is unusual 
because EGFR, KRAS, and ALK mutations are widely 
known as mutually exclusive. Most are associated with 
acquired mutation after targeted therapy and are related to 
drug resistance [10]. 
 Wang et al in their study found the distribution to be 
239 (79.67%) cases of squamous cell carcinoma, 
adenocarcinoma in 36 cases (12%) and adenosquamous 
carcinoma 10 cases ( 3.33%). In our study, the distribution 
of nonsmall cell carcinoma was found to be 
adenocarcinoma 36.23% (50/138) and squamous cell 
carcinoma 63.7% (88/100). Ture et al and Wang et al in 
their study found male population predominant in lung 
carcinoma, 74.2% (98/132) and 59.33% (178/300) 
respectively [6,8]. In our study we also found 72.7% of 
patients of lung carcinoma were males with an average age 
of 63.2 yrs. 
CONCLUSION 
Histomorphological examination and Immunohisto-
chemistry are essential for a definite diagnosis of non-
small cell lung carcinoma. EGFR mutation, single and 
concomitant with ALK mutation is the most common 
genetic alteration seen in patients diagnosed as adeno 
carcinoma among non-small cell carcinoma cases. Males 
with smoking history with more than ten years are at risk 
for developing lung carcinoma. 
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